In development, epithelial-mesenchymal transition (EMT) allows interconnected sheets of epithelial cells to reorganize and to pass into and through the surrounding extracellular matrix (ECM). In cancer, EMT-associated processes facilitate invasive growth and development of metastases. Matrix metalloproteinases (MMPs) are enzymes capable of degrading the ECM and altering cell-cell and cell-ECM interactions. MMPs are upregulated in nearly all tumor types, have been shown to induce EMT in cultured cells, and are involved in the development of tumor formation, invasion, and metastasis. We have identified the induction of Rac1b, an alternatively spliced variant of Rac1, as a key event in MMP-induced EMT. Induction of the Rac1b isoform leads to increased cellular reactive oxygen species (ROS), which causes in turn upregulation of Snail, a transcription factor previously implicated in physiological and pathological EMT. MMP/Rac1b-induced ROS also causes DNA damage and induces genomic instability. These findings reveal a new pathway in which a key element of the tumor microenvironment directly stimulates the phenotypic and genotypic alterations involved in malignant transformation, and provides many opportunities for investigation of therapeutic interventions.

Keywords:
Mammary development, Rac1b, Epithelial-mesenchymal transition
This content is only available via PDF.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.